Critical care medicine is an important and inseparable part of modern medical provision. Intensive care units (ICUs), although costly, are an essential element in the delivery of critical care. ICUs are characterized by hi-tech monitoring capabilities as well as increased density of medical and nursing staff compared with general wards or intermediate-care units. However, not all patients for whom ICU admission is indicated are actually admitted to ICU. There are several reasons for this inadequate delivery of care, including [1] lack of sufficient resources to create enough ICU beds and [2] failure of the treatment team outside the ICU to recognize the severity of the disease or the risk of deterioration of a currently stable situation.
With regard to the first point, because not all patients require the use of all resources available in the ICU many hospitals in Europe have created intermediate-care units. These units typically provide more intensive monitoring and patient management than general wards, with higher nurse-patient ratios. These units have been implemented in Europe in the past 10 years; however, a debate is still ongoing [1] about their specific location and organization. The existence of these units is a solution for postoperative monitoring, for patients with single-organ failure, and for those at risk of deterioration during the evolution of their disease.
The second point is particularly important since there is a population, difficult to recognize, that could benefit from ICU admission. Recognition of patients that might need ICU care after hospital admission is not easy and requires validated tools. One illustrative example is severe community-acquired pneumonia, which can usually be detected in the emergency department (ED) using standard criteria [2] . When there is a delay in admitting these patients to the ICU, mortality doubles (50 %) [3] . Possession of tools to monitor patients at risk is extremely important. Renaud and colleagues [4] developed the REA-ICU index, based on data obtained from four prospective multicenter studies in adults with pneumonia (two from North America and two from Europe). Of the 6560 patients included in the study, 303 (4.6 %) had no clear indication for ICU admission at presentation but required intensive care in the following 3 days. The authors developed a score comprising 11 variables enabling stratification of patients into four classes of risk for ICU admission on days 1 to 3 (risk increasing from 0.7 to 31 %). An approach like this may help ED physicians and intensivists in the decision to admit patients to ICU or intermediate-care units.
Despite adequate preoperative assessment of risk, postoperative patients can develop unpredicted complications requiring ICU admission. In these patients (both trauma and pre-/postoperative) a relatively simple score has been validated for early detection of risk for severe morbidity and mortality [5, 6] . However, these scoring systems detect problems that already exist. So alongside early detection of a deteriorating system, predicting the high likelihood that this will occur in the near future is especially interesting. The latter might not only result in better outcomes but also improve efficiency of care.
Another point related to potential deterioration of patients that initially do not need intensive care is a poor standard of care. This is even more important as it is amenable to medical intervention. Studies on quality of care improvements and scoring systems to assess quality of care that might result in more timely admission of patients to the ICU could thus have a great impact.
Finally, patients with do-not-resuscitate (DNR) orders or end-of-life status constitute an important population that would benefit from ICU admission to receive transient and palliative specialized intensive care [7] .
Intensive care outside the ICU is a very broad field (Table 1) . Recently, Intensive Care Medicine launched a call for papers on perioperative critical care [8] . Now, we are launching a call for manuscripts on the topic of hospitalized patients at risk of dying. This new call is aimed at both medical and surgical researchers and is open to all specialties. We feel that Intensive Care Medicine is an excellent setting and opportunity for this type of article. We can fast-track these manuscripts, with rapid and fair peer review. We hope that this call will receive many positive responses.
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